medigraphic.com

2013, Number 4

<< Back Next >>

Rev Hosp Jua Mex 2013; 80 (4)

Hipertensión arterial pulmonar asociada a esclerodermia en mestizos mexicanos

Lugo-Zamudio GE, Sepúlveda-Aldana D, García-Mayen LF, López-Gómez LM, Barbosa-Cobos RE, Delgado-Ochoa MD

Language: Spanish
References: 16
Page: 231-234
PDF size: 175.37 Kb.


ABSTRACT

Introduction. The diagnosis of pulmonary arterial hypertension (HAP) in esclerodermia (SSc) is not made of early way, which is significant since this complication is one of the main causes of mortality and morbidity in SSc. In the Mexican mestizo the prevalence of HAP is not known. Material and methods. Clinical, non-experimental, cross-sectional and opened, in patients with SSc, carrying out echocardiogram Doppler color (ECD), tests of respiratory function (PFR), anticentromere determination of antibodies (AAC) and antitopoisomerase (AAT). Analyzing prevalence of the HAP, correlation between the time of evolution of SSc and it is present at (Yes/No) of HAP with test χ2, the relation between time of evolution of SSc and values of the systolic pressure of the pulmonary artery (PSAP), relation between HAP and the fraction of expulsion of the left ventricle (FEVI), statistical program used IBM SPSS version 20. Results. We included 35 patients, the associated diffuse variety to the AAC is observed most frequently, not showing positive correlation with HAP. The PFR show pulmonary commitment in the 68.8% of the cases, without correlation with HAP, by ECD the prevalence of HAP is documented in 34.3% of the cases, with PSAP › 36 mmHg, the time of evolution of the disease and the PSAP shows positive correlation (0.569). Conclusions. The prevalence of HAP in the Mexican mestizo with SSc is significant, our results suggest the ECD must be including within the initial protocol and subsequent evaluation of the patients with this pathology.


REFERENCES

  1. Arnett FC. HLA and autoinmunity in scleroderma. Int Rev Inmunol 1995; 12(2): 107-28.

  2. Vera LastraL, Jiménez S. Esclerosis Sistémica. 1a Ed. México, D.F.: Elsevier 2009, p. 131-40.

  3. Dángelo WA, Fries JE, Mn AT, Shulman LE. Pathologic observations in systemic scleroderma. Am J Med 1969; 46: 428-40.

  4. König G, Luderschmidt C, Hammer C, Bernard C, Grill A. Lung involvemet in scleroderma. Chest 1984; 85: 319.

  5. Farber W. Pulmonary Arterial Hypertension. NEJM 2004; 351: 1655-65.

  6. Minai O. Diagnostic strategies for suspected pulmonary arterial hypertension. Clev Clin J Med 2007; 74: 737-47.

  7. Simonneau G, Galié N, Rubin L, et al. Clinical classification of pulmonary arterial classification. J Am Coll Cardiol 2004; 43: S5-S12.

  8. Weaver AL, Divertie MB, Titus JL. Pulmonary scleroderma. Chest 1968; 490-9.

  9. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical and serologic features and survival in 1012 Italian patients. Medicine 2002; 81: 139-53.

  10. Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheum Dis Clin N Am 1996; 22: 841.

  11. Denton CP, Cailes JB, Phillips GD, et al. Comparision of Doppler echocardiography and right catheterization to asses pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997; 36(2): 239-43.

  12. Champion H. The heart in scleroderma. Rheum Dis Clin N Am 2008; 34: 181.

  13. Hoeper MM, Oudiz RJ, Peacock A, Frost AE, et al End points and clinical trial designs in pulmonary arterial hypertension clinical and regulatory perspectives. J Am Coll Cardiol 2004; 16(12 Suppl.): 48S-55S.

  14. Koh Et, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in Systemic Sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-93.

  15. Ostojic P, Cericic MM, Silver R, Highland K, Damjanov N. Interstial Lung Disease in Systemic Sclerosis. Lung 2007; 185: 211-20.

  16. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dysnea. Contents interobserver agreement and physiologic correlates of two new clinical indexes. Chest 1988; 85: 751-8.




2020     |     www.medigraphic.com